Milenko Kujovic
Overview
Explore the profile of Milenko Kujovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kujovic M, Bahr C, Riesbeck M, Benz D, Deiss M, Margittai Z, et al.
Borderline Personal Disord Emot Dysregul
. 2025 Jan;
12(1):2.
PMID: 39810278
Background: Dialectical behavioral therapy (DBT) and repetitive transcranial magnetic stimulation (rTMS) are both effective in treating borderline personality disorder (BPD). Impulsivity and impaired decision-making are prominent features of BPD, and...
2.
Meisenzahl E, Schultze-Lutter F, Stegmuller V, Schulte-Korne G, Greimel E, Klingele C, et al.
Front Psychiatry
. 2024 Oct;
15:1389370.
PMID: 39403320
Introduction: Early recognition and indicated prevention is a promising approach to decrease the incidence of Major depressive episodes (MDE), targeting the patients during their clinical high-risk state of MDE (CHR-D)....
3.
Kujovic M, Bahr C, Riesbeck M, Benz D, Wingerter L, Deiss M, et al.
Eur Arch Psychiatry Clin Neurosci
. 2024 Sep;
PMID: 39297977
Dialectical behavioral therapy (DBT) and repetitive transcranial magnetic stimulation (rTMS) are both effective in borderline personality disorder (BPD). We hypothesized that intermittent theta burst stimulation (iTBS), a modified rTMS protocol...
4.
Kujovic M, Benz D, Riesbeck M, Mollamehmetoglu D, Becker-Sadzio J, Margittai Z, et al.
Sci Rep
. 2024 May;
14(1):11264.
PMID: 38760498
Dialectical behavior therapy (DBT) is widely acknowledged as an effective treatment for individuals with borderline personality disorder (BPD). However, the optimal treatment duration within DBT remains a topic of investigation....
5.
Kujovic M, Benz D, Riesbeck M, Bahr C, Kriegs C, Reinermann D, et al.
Eur Arch Psychiatry Clin Neurosci
. 2023 Sep;
274(1):87-96.
PMID: 37710135
Specialized psychotherapeutic treatments like dialectical behavioral therapy (DBT) are recommended as first treatment for borderline personality disorder (BPD). In recent years, studies have emerged that focus on repetitive transcranial magnetic...
6.
Michael A, Michael N, Erfurth A, Kujovic M
Psychogeriatrics
. 2023 Sep;
23(6):963-972.
PMID: 37673659
Background: Distressing behavioural symptoms, particularly agitation and aggressiveness, remain a difficult problem in everyday clinical practice in the treatment of multimorbid patients with dementia. Clozapine may be an effective therapeutic...
7.
Kujovic M, Lipka T, Zalman M, Baumann L, Janner M, Baumann B
Sci Rep
. 2023 May;
13(1):7556.
PMID: 37160982
The aim of this study was to investigate the effect of arterial hypertension (AH) and of obstructive sleep apnea (OSA) on cognitive course in the neurocognitive disorder (NCD) cohort RIFADE...
8.
Baumann B, Lipka T, Janner M, Kujovic M
Eur Arch Psychiatry Clin Neurosci
. 2022 Nov;
273(4):941-952.
PMID: 36416960
Background: The NCD cohort study RIFADE (RIsk FActors of DEmentia) investigates the interaction of risk factors and neurocognitive disorders (NCDs) due to Alzheimer's disease (NCD-AD) and NCD of vascular type...
9.
Askari I, Wenglorz L, Gajewski F, Janner M, Vetter A, Askari A, et al.
Curr Psychol
. 2022 May;
:1-10.
PMID: 35600263
The year 2020 saw the emergence of a worldwide pandemic caused by the novel coronavirus COVID-19. Measures against further spread of the virus were taken nearly everywhere in the world....
10.
Schmidt-Kraepelin C, Meisenzahl-Lechner E, Kujovic M, Cordes J, Engelke C, Riesbeck M, et al.
Psychiatr Prax
. 2021 Jan;
48(5):250-257.
PMID: 33472267
Background: Antipsychotics are the cornerstone in the treatment of schizophrenia and are primarily recommended as monotherapy by evidence-based guidelines. Nevertheless, antipsychotic polypharmacy (APP) is prevalent in routine practice and APP...